1. Home
  2. TVRD vs PAMT Comparison

TVRD vs PAMT Comparison

Compare TVRD & PAMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • PAMT
  • Stock Information
  • Founded
  • TVRD 2017
  • PAMT 1980
  • Country
  • TVRD United States
  • PAMT United States
  • Employees
  • TVRD N/A
  • PAMT 2304
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • PAMT Trucking Freight/Courier Services
  • Sector
  • TVRD Health Care
  • PAMT Industrials
  • Exchange
  • TVRD Nasdaq
  • PAMT Nasdaq
  • Market Cap
  • TVRD 246.5M
  • PAMT 223.5M
  • IPO Year
  • TVRD N/A
  • PAMT 1985
  • Fundamental
  • Price
  • TVRD $6.73
  • PAMT $11.22
  • Analyst Decision
  • TVRD Buy
  • PAMT Hold
  • Analyst Count
  • TVRD 7
  • PAMT 1
  • Target Price
  • TVRD $51.67
  • PAMT $13.00
  • AVG Volume (30 Days)
  • TVRD 467.6K
  • PAMT 9.3K
  • Earning Date
  • TVRD 11-21-2025
  • PAMT 10-24-2025
  • Dividend Yield
  • TVRD N/A
  • PAMT N/A
  • EPS Growth
  • TVRD N/A
  • PAMT N/A
  • EPS
  • TVRD N/A
  • PAMT N/A
  • Revenue
  • TVRD N/A
  • PAMT $655,581,000.00
  • Revenue This Year
  • TVRD N/A
  • PAMT N/A
  • Revenue Next Year
  • TVRD N/A
  • PAMT $12.19
  • P/E Ratio
  • TVRD N/A
  • PAMT N/A
  • Revenue Growth
  • TVRD N/A
  • PAMT N/A
  • 52 Week Low
  • TVRD $5.65
  • PAMT $10.51
  • 52 Week High
  • TVRD $43.65
  • PAMT $23.70
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 20.91
  • PAMT 37.37
  • Support Level
  • TVRD $5.65
  • PAMT $10.51
  • Resistance Level
  • TVRD $7.11
  • PAMT $10.97
  • Average True Range (ATR)
  • TVRD 2.47
  • PAMT 0.37
  • MACD
  • TVRD -4.16
  • PAMT -0.06
  • Stochastic Oscillator
  • TVRD 3.26
  • PAMT 9.47

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About PAMT PAMT CORP Common Stock

PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.

Share on Social Networks: